2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.17A.04 Real-World Rates of Infusion-Related Reactions in Patients with EGFR-Mutant NSCLC Receiving Amivantamab

EP.17A.04 Real-World Rates of Infusion-Related Reactions in Patients with EGFR-Mutant NSCLC Receiving Amivantamab

Pdf Summary

The study conducted by Divya M. Gupta and colleagues at Northwestern University investigated the real-world rates and severity of infusion-related reactions (IRRs) in patients with EGFR-mutant non-small cell lung cancer (NSCLC) treated with amivantamab. Amivantamab, an EGFR-MET bispecific antibody, is recommended for use in these patients, particularly after progression on osimertinib for those with classical EGFR mutations. Clinical trials typically report grade 3 and 4 IRRs in 1-5% of cases. <br /><br />The retrospective study assessed 33 patients treated with amivantamab from January 2021 to February 2024, focusing on demographics, pre-medications, IRR rates and severity, emergency responses, and treatment discontinuations. Results showed that 82% of patients experienced IRRs, with a notably high rate of grade 3/4 IRRs at 48% during the first cycle, much higher than clinical trial data. All patients experienced IRRs on the first day of the first cycle, and emergency responses were necessitated in certain cases. <br /><br />Despite the high incidence of severe IRRs, most patients continued treatment, indicating manageable conditions with available resources. The study highlights the significant safety concerns associated with high-grade IRRs, especially in infusion centers with limited emergency facilities. It calls attention to substantial resource needs and potential exacerbation of healthcare disparities.<br /><br />The study also points towards subcutaneous administration of amivantamab as a less resource-intensive alternative, with a reduced IRR rate of 16% and significantly shorter initial administration time compared to the intravenous method. These findings suggest further research is needed to mitigate IRR risks, ensuring safe and equitable access to amivantamab across different healthcare settings.

Asset Subtitle

Divya Gupta

Meta Tag

Speaker Divya Gupta

Topic Global Health, Health Services, and Health Economics

Keywords

EGFR-mutant NSCLC

amivantamab

infusion-related reactions

IRR severity

EGFR-MET bispecific antibody

clinical trial comparison

emergency response

healthcare disparities

subcutaneous administration

resource needs